Breast Cancer
News
MONARCH 1: Abemaciclib is active in refractory HR+, HER2– breast cancer
Key clinical point: The cell cycle inhibitor abemaciclib is active in refractory HR+, HER2– metastatic breast cancer. Major finding: The overall...
Video
VIDEO: Dr. Rugo discusses regulatory future for trastuzumab biosimilar
News
Biosimilar trastuzumab comparable on safety, efficacy
Key clinical point: MYL-1401O is comparable in safety and efficacy to trastuzumab for women with HER2-positive advanced breast cancer. Major...
Conference Coverage
Targeting vagal activity could improve breast cancer survival
Vagal activity predicts survival in patients with metastatic or recurrent breast cancer, a study found.
News
Investigational CDK4/6 inhibitor shows activity, less toxicity
Key clinical point: A phase I trial indicates that abemaciclib is safe and shows activity in treating patients with advanced breast and other...
Case Reports
Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy
Original Report
Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus
Reviews
Effects of exercise interventions during different treatments in breast cancer
News
Full course of AI keeps disease at bay longer
Key clinical point: Early cessation of aromatase inhibitor therapy is associated with reduced disease-free survival in postmenopausal women with...
News
High ER expression + high RS spells high risk for late distant recurrence
Key clinical point: A 21-gene recurrence score is strongly prognostic for late distant recurrence of breast cancer in patients with higher...
News
ASCO issues guidelines for HR+ metastatic breast cancer
Key clinical point: Hormonal therapy should be offered to patients whose tumors express any level of estrogen and/or progesterone receptors,...